Navigation Links
Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Date:9/5/2007

Lung Cancer

SCLC is the most aggressive and deadly form of lung cancer and accounts for approximately 20 percent of all lung cancer cases. The current two-year survival rate for patients with extensive SCLC is less than 10 percent with current management options. The estimated incidence of lung cancer in the United States in 2006 was 174,500, according to the National Cancer Institute. The estimated incidence in Europe in 2006 was 386,300, according to the International Agency for Research on Cancer.

SCLC is currently treated with platinum therapies, but many patients do not respond, and if they do respond, they typically relapse within a short time after treatment. There is currently no FDA-approved therapy and no consistent and effective therapy for SCLC patients who have platinum-resistant or -refractory disease after treatment failure with first-line combination therapy with either cisplatin or carboplatin. No new drugs have been approved by the FDA for the treatment of platinum-resistant or -refractory SCLC in nearly a decade.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional infor
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... July 31, 2015 RnRMarketResearch.com ... market research report that provides an overview of ... data sourced from in-house databases, secondary and primary ... needles market products pipeline spread across 124 pages, ... 73 tables and 5 figures is now available ...
(Date:7/31/2015)... TAMPA, Fla. , July 31, 2015 /PRNewswire/ ... announced today that it has made a structured ... -based company specializing in milling, micronization and ... investment will help grow Powdersize,s business while simultaneously ... solutions to Xcelience,s portfolio of capabilities. ...
(Date:7/31/2015)... and SAN DIEGO , ... its parent company Eisai Co., Ltd. (Headquarters: ... , "Eisai") and Halozyme Therapeutics, Inc. (Headquarters: ... Helen Torley , "NASDAQ: HALO") have signed a ... name: Halaven ® , "eribulin") in combination with Halozyme,s ...
Breaking Medicine Technology:Syringes and Needles Market Products Pipeline Review 2015 Report 2Syringes and Needles Market Products Pipeline Review 2015 Report 3Syringes and Needles Market Products Pipeline Review 2015 Report 4Syringes and Needles Market Products Pipeline Review 2015 Report 5Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6
... 22 Xoft, makers of Electronic Brachytherapy systems ... integration of its Axxent® Electronic Brachytherapy System at the ... fully comprehensive breast center exclusively dedicated to the prevention, ... Lotus Breast Center is the first comprehensive breast center ...
... Baxano, Inc. ( www.baxano.com ) today announced the closing ... funding, led by new investor CMEA Capital.   Funds were also ... and existing investors Prospect Venture Partners, Three Arch Partners, and Kearny ... , ...
Cached Medicine Technology:Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform 2Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform 3Baxano, Inc. Announces Close of $30 Million Series C Funding 2
(Date:8/2/2015)... Ky. (PRWEB) , ... August 03, 2015 , ... A ... recurrence of some childhood cancers. The study is led by Kenneth G. Lucas, ... the University of Louisville in collaboration with colleagues at Kosair Children’s Hospital ...
(Date:8/1/2015)... (PRWEB) , ... August 02, 2015 , ... AlignLife ... which will help the continuity of care for patients at this natural health care ... the unknown," Clinic Director Mary Heal said. "Heather's role is vital to our approach ...
(Date:8/1/2015)... Humble, TX (PRWEB) , ... August 01, 2015 , ... ... common concern among both men and women often causing pain and discomfort. Those who ... to this circulatory problem, and Northeast Houston Vein Center is doing what it can ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... 2015 , ... “ reTXT ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... edit and delete any message including ones already sent. , While text messaging has ...
Breaking Medicine News(10 mins):Health News:UofL Physicians Conducting Vaccine Trial for Children with Relapsed Tumors at Kosair Children’s Hospital 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2
... Senate to Introduce and Pass an Identical Bill, ... of Representatives for passing H.R. 1943, The Stop AIDS,in ... by Rep. Maxine Waters,(D-CA) in April would provide routine ... release from federal prisons and allow,inmates to request an ...
... found significant improvement in symptoms and productivity , , TUESDAY, ... who participated in a workplace program that used a ... improvement in their symptoms as well as greater productivity. ... in the Sept. 26 issue of the Journal ...
... Boise,s Leadership in the ... Premium and Specialty Papers Market, BENSENVILLE, Ill., Sept. ... announced that Boise(R) BEWARE(TM), an,anti-copy/anti-scan paper is in compliance with ... legislation,will go into affect on October 1, 2007. Boise(R) ...
... 25 Experts in health care and,technology investment ... technology-based economic growth in Ohio today at the ... These experts will help,shape Ohio,s future as it ... environment for the State of Ohio is changing," ...
... an eating disorder, it is not known whether there are ... Now, a new study finds that women with anorexia ... of the brain that is important for recognizing taste ... University of California, San Diego researchers currently on line in ...
... MANCHESTER, N.H., Sept. 25 Presidential,candidate Senator John ... cost-effective approach towards stopping HIV/AIDS in the US ... address violence against,women and to provide reproductive health ... ideas in Senator Edwards, plan,especially his proposal on ...
Cached Medicine News:Health News:House of Representatives Passes Stop AIDS in Prison Act of 2007 2Health News:Treatment Programs Benefit Depressed Workers 2Health News:Treatment Programs Benefit Depressed Workers 3Health News:Boise(R) BEWARE(TM) Meets New Federal Guidelines Set Forth by Medicaid 2Health News:Experts Agree. Ohio's Technology Investment Future Looks Bright 2Health News:Experts Agree. Ohio's Technology Investment Future Looks Bright 3Health News:Sense of taste different in women with anorexia nervosa 2Health News:Exciting New Plan from John Edwards on AIDS; Plan is 'Bold and Achievable,' say New Hampshire Activists 2
... camera system designed for scientific microscope ... digital cameras provides high-resolution, full-color images ... a PC via its Firewire (IEEE ... capability is accompanied by automatic white ...
... is a fully automatic fluorescence photomicrography system ... of even the most difficult specimens. Designed ... PM20 system provide solution to the complex ... their automatic exposure control, the system utilizes ...
... Digital camera systems for optimum image quality ... digital camera system is specifically designed for ... State-of-the-art electronics create bright, vibrant images without ... range offered by the Leica cameras allow ...
... for optimum image quality at low ... system records live cells, motion sequences ... times at the lowest light intensity. ... spectrum assure reliable results in GFP ...
Medicine Products: